HOME >> BIOLOGY >> NEWS
Sidebar: new trial should lead to better understanding of why exercise is an effective treatment for depression

DURHAM, N.C. -- The Duke University Medical Center researchers who found evidence that exercise can be an effective treatment for major depression are embarking on a larger trial they believe will answer some of the remaining questions posed by their earlier results.

The new trial, which is being funded by a $3 million grant from the National Institute of Mental Health, is designed to further refine which depressed patients can benefit from exercise and determine why exercise appears to be effective. Additionally, the study will measure the effect of exercise on a phenomenon known as vascular depression, a form of depression that appears linked to actual abnormalities in blood vessels of the brain, and not brain chemical imbalances. The previous Duke studies, led by psychologist James Blumenthal, found that exercise was just as effective as the most common anti-depressive medication in reducing the symptoms of major depression.

"This new trial is intended to answer some of the whys' posed by those original studies," Blumenthal explained. "We are very interested in evaluating behavioral, non-pharmacologic approaches to treating depression. Because up to one-third of depressed patients may not respond to drug therapy, and those who do take drugs may complain of side effects, it is important to find other approaches."

Over the next five years, the researchers plan to enroll 216 volunteers, half of whom will be assigned randomly to the drug arm of the trial and half to the exercise arm. The drug to be used is sertraline (trade name Zoloft), a member of a class of commonly used anti-depressants known as selective serotonin reuptake inhibitors, and the same drug used in the earlier trials.

Unlike the earlier trials, the new trial will have a placebo, or ineffective sugar pill, arm. Also unlike the earlier trials, the exercise arm will be divided as well -- half of the patients will do thei
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
20-Sep-2000


Page: 1 2 3

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... 2017 , ... DaVita Clinical Research (DCR), a ... device development, and Prism Clinical Research , a leader in providing fully ... Clinical Trials (VCT) has been selected by both companies as an exclusive ...
(Date:1/18/2017)... Portland, OR (PRWEB) , ... January 18, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... Altera Cyclone V E FPGA into a compact business-card sized form factor suitable ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Researchers from a new study are ... fall low enough after prostate cancer treatment, this indicates there is still remaining prostate cancer ... mortality. , “ The PSA test has always been an indicator of whether a man’s ...
Breaking Biology Technology:
Cached News: